Swedish medical technology company Qlife Holding AB (STO: QLIFE), which develops the Egoo Health at-home diagnostics platform, said on Friday that its system will be used in a performance evaluation study led by Hipro Biotechnology Co., Ltd. in collaboration with Beijing Tsinghua Changgung Hospital.

The project aims to advance an AI-assisted precision care system designed to improve remission and management of Type 2 diabetes and metabolic dysfunction-associated steatotic liver disease in China.

The hospital will use the Egoo HbA1c test, which is not yet approved for sale, and the results will support a later regulatory submission. The initiative seeks to address rising disease burdens and limitations in traditional treatment models by shifting chronic care from hospital-centric approaches to proactive, technology-enabled management.

Egoo Health enables patients to perform clinical-grade diagnostics at home, including HbA1c, urinary microalbumin, creatinine, and lipid tests. Its accuracy and portability are intended to reduce reliance on hospital visits and strengthen continuity of care.

The partnership also incorporates an AI-driven digital twin platform that brings together expertise from multiple clinical and lifestyle disciplines to provide real-time monitoring, tailored nutrition plans, and behavioural support. The combined model aims to deliver continuous co-management by specialists and digital tools, creating a comprehensive framework for long-term disease control.